Abstract Number: 2555 • ACR Convergence 2025
Ergonomic Modifications: Findings From the Making it WorkTM Systemic Sclerosis Program
Background/Purpose: Work disability in people with systemic sclerosis (SS) increases substantially from diagnosis to three years after disease onset. Ergonomic modifications help people with physical,…Abstract Number: 2482 • ACR Convergence 2025
Characterizing Gastrointestinal Involvement in Systemic Sclerosis: Insights from the National Systemic sclerosis Progression INvestiGation (SPRING) Registry of the Italian Society of Rheumatology
Background/Purpose: Gastrointestinal (GI) involvement affects over 80% of patients with systemic sclerosis (SSc), contributing significantly to morbidity and representing the third leading cause of disease-related…Abstract Number: 1868 • ACR Convergence 2025
Global Downregulation of Fli1 in Mice Induces Cardiac Dysfunction via Enhanced β-fatty acid Oxidation and Collagen Deposition
Background/Purpose: Primary cardiac involvement is a common complication of Systemic sclerosis (SSc), characterized by fibrosis and diastolic dysfunction, presumably due to microvascular dysfunction and repeated…Abstract Number: 1581 • ACR Convergence 2025
The Overall Prevalence and Associated Disease Characteristics of Calcinosis in Systemic Sclerosis: a Systematic Review and Meta-analysis
Background/Purpose: Calcinosis is a high-burden, key manifestation of systemic sclerosis (SSc), with a challenging therapeutic management. Yet, its precise prevalence and association with SSc charcateristics…Abstract Number: 1537 • ACR Convergence 2025
Local Immune effector Cell-Associated Toxicity Syndrome (LICATS) in CAR T-cell treated patients with Autoimmune Disease
Background/Purpose: CD19-targeting chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment strategies for severe B-cell driven autoimmune diseases (AID) like Systemic Lupus erythematosus (SLE), Systemic…Abstract Number: 0969 • ACR Convergence 2025
FOXO1 Mediated Polysialic Acid Dysregulation in Severe Systemic Sclerosis (SSc): A Novel Biomarker and Therapeutic Target?
Background/Purpose: Systemic sclerosis (SSc) is a life-threatening autoimmune disease where fibroblasts (FB) contribute to disease severity by resisting apoptosis and driving excessive skin fibrosis. Among…Abstract Number: 0700 • ACR Convergence 2025
Distinct Breath Metabolomic Signature in Systemic Sclerosis Patients with Pulmonary Arterial Hypertension
Background/Purpose: Pulmonary arterial hypertension (PAH) is a severe complication of systemic sclerosis (SSc), associated with high morbidity and mortality. Accurate and early diagnosis of SSc-PAH…Abstract Number: 0672 • ACR Convergence 2025
Determinants of Progressive Microstomia in Systemic Sclerosis: Insights from the GENISOS Cohort with a Focus on GI Involvement
Background/Purpose: Systemic sclerosis (SSc) is a complex autoimmune condition characterized by vascular abnormalities, immune dysregulation, and progressive fibrosis affecting both the skin and internal organs.…Abstract Number: 0808 • ACR Convergence 2025
Spatial Transcriptomics Show Fibroblast LIF Receptor Drives Fibrosis in Systemic Sclerosis
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune, fibroinflammatory disease of skin and visceral organs. Current SSc therapies have limited efficacy for progressive fibrosis. Our prior…Abstract Number: 2503 • ACR Convergence 2025
Validation of a Composite Biomarker Score To Predict Modified Rodnan Skin Score: Insight From Autologous Stem Cell Transplantation International Scleroderma trial
Background/Purpose: Skin fibrosis is a cardinal manifestation of diffuse cutaneous systemic sclerosis (dcSSc) and is routinely measured via the modified Rodnan skin score (mRSS); however,…Abstract Number: 2480 • ACR Convergence 2025
Respiratory Muscle Weakness in a Systemic Sclerosis Cohort
Background/Purpose: Systemic sclerosis (SSc) is a complex autoimmune disorder marked by vascular damage, immune dysregulation, and fibrosis. Lung involvement, particularly interstitial lung disease (ILD), carries…Abstract Number: 1867 • ACR Convergence 2025
Deciphering the Molecular Landscape of the Small Intestine in Early and Late SSc Using High-Definition Spatial Transcriptomics
Background/Purpose: SSc frequently results in serious gastrointestinal (GI) complications that contribute to increased morbidity and mortality. Understanding the molecular changes across different disease stages is…Abstract Number: 1580 • ACR Convergence 2025
Lung vasculature quantification on computed tomography predicts new onset of interstitial lung disease in systemic sclerosis
Background/Purpose: Interstitial lung disease (ILD) is highly prevalent in systemic sclerosis (SSc) and a leading cause of mortality. Recent studies have identified clinical risk factors…Abstract Number: 1199 • ACR Convergence 2025
Interstitial Lung Disease in Systemic Autoimmune Rheumatic Diseases (SARDs): Radiologic and Histologic Correlations
Background/Purpose: Systemic autoimmune rheumatic diseases (SARDs) are a major cause of interstitial lung disease (ILD), with high prevalence in inflammatory idiopathic myopathy (IIM), systemic sclerosis…Abstract Number: 0967 • ACR Convergence 2025
Single-Cell RNA Sequencing Reveals a Prominent Pro-Inflammatory Gene Signature of Dermal Fibroblasts in Pre-Stages of SSc
Background/Purpose: The poor prognosis of SSc patients demands an urgent need to prevent disease onset. Recently, we reported a global pro-inflammatory gene signature of dermal…
- 1
- 2
- 3
- …
- 56
- Next Page »
